Почетна › Карцином на јајниците › Северна Каролина › Durham
Клинички испитувања за Карцином на јајниците во Durham, NC
27 студии за Карцином на јајниците бараат учесници на локации во и околу Durham (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
The Vanguard Study: Testing a New Way to Screen for Cancer
Се регрутираДобредојдени се здрави волонтери
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 милји
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Се регрутираФаза 2/3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 милји
- University of North Carolina-Hillsborough Campus, Hillsborough · на 13 милји
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Се регрутираФаза 2
- Duke University Medical Center, Durham
A Study of PHST001 in Advanced Solid Tumors
Се регрутираФаза 1
- Duke Cancer Institute, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Се регрутираФаза 1/2
- Duke University, Durham
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Се регрутираФаза 2
- University of North Carolina Medical Center /ID# 275307, Chapel Hill · на 10 милји
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Се регрутираФаза 2
- Site 0259 - Duke Cancer Center, Durham
DESTINY-PANTUMOUR04
Се регрутираНабљудувачка студија
- Research Site, Durham
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Се регрутираФаза 3
- Duke Cancer Institute, Durham
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Се регрутираФаза 1
- Duke University Medical Center, Durham
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Се регрутираФаза 3
- Duke Cancer Center ( Site 0012), Durham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Се регрутираНабљудувачка студија
- UNC- Chapel Hill, Chapel Hill · на 10 милји
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Се регрутираФаза 3
- Duke, Durham
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Се регрутира
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 милји
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Се регрутираФаза 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 милји
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Се регрутираФаза 1/2
- Duke University, Durham
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Се регрутираФаза 3
- UNC Hospital, Chapel Hill · на 10 милји
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Се регрутираФаза 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 милји
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Се регрутираФаза 3
- Duke Cancer Center, Durham
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Се регрутира
- Duke Cancer Center, Durham
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Се регрутираФаза 1
- Site 0259, Durham
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Се регрутира
- Duke University Hospital, Durham
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Се регрутираФаза 1/2
- Duke Cancer Center/ DUMC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Се регрутираФаза 1
- Duke Cancer Institute, Durham
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Се регрутираФаза 2
- Duke Cancer Center, Durham
Multimedia Aid for Genetic Testing in Gynecologic Oncology
Се регрутира
- Univeristy of North Carolina at Chapel Hill, Chapel Hill · на 10 милји
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Се регрутираНабљудувачка студија
- Massive Bio SYNERGY-AI site, Chapel Hill · на 10 милји
Испитувања за Карцином на јајниците во други градови
- Houston, TX89 студии
- New York City, NY69 студии
- Boston, MA61 студија
- Los Angeles, CA50 студии
- Nashville, TN49 студии
- Arlington, VA46 студии
- Philadelphia, PA44 студии
- Columbus, OH39 студии
- St. Louis, MO38 студии
- Chicago, IL36 студии
- San Antonio, TX31 студија
- Cleveland, OH30 студии
Други студии во Durham
- Рак на дојка64 студии
- Рак (сите типови)58 студии
- Рак на бели дробови со не-мали клетки39 студии
- Множен миелом37 студии
- Акутна миелоидна леукемија33 студии
- Метастатски карцином33 студии
- Рак на простата32 студии
- Рак на бели дробови32 студии
- Колоректален карцином28 студии
- Хронична лимфоцитна леукемија27 студии
- Срцева слабост26 студии
- Карцином на панкреасот24 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.